GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GRAL GRAIL, Inc.

已收盘 11-10 16:00:00 EST

124.74

-3.34

-2.61%

盘后125.17

+0.43+0.34%

19:58 EST

最高127.70	最低120.41	成交量66.80万
今开125.88	昨收128.08	日振幅5.69%
总市值56.09亿	流通市值51.20亿	总股本4,496万
成交额8,284万	换手率1.63%	流通股本4,104万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GRAL","market":"US","secType":"STK","nameCN":"GRAIL, Inc.","latestPrice":124.74,"timestamp":1794344400000,"preClose":128.08,"halted":0,"volume":667986,"hourTrading":{"tag":"盘后","latestPrice":125.17,"preClose":124.74,"latestTime":"19:58 EST","volume":41377,"amount":5159844.1413,"timestamp":1794358732797,"change":0.43,"changeRate":0.003447,"amplitude":0.023409},"delay":0,"changeRate":-0.026077451592754663,"floatShares":41043339,"shares":44962171,"eps":-9.265754,"marketStatus":"已收盘","change":-3.34,"latestTime":"11-10 16:00:00 EST","open":125.88,"high":127.7,"low":120.41,"amount":82838707.34304,"amplitude":0.056918,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.265754,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1794387600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":128.08,"preHourTrading":{"tag":"盘前","latestPrice":125.66,"preClose":128.08,"latestTime":"09:29 EST","volume":589,"amount":74897.27534000001,"timestamp":1794320999999,"change":-2.42,"changeRate":-0.018894,"amplitude":0.032324},"postHourTrading":{"tag":"盘后","latestPrice":125.17,"preClose":124.74,"latestTime":"19:58 EST","volume":41377,"amount":5159844.1413,"timestamp":1794358732797,"change":0.43,"changeRate":0.003447,"amplitude":0.023409},"volumeRatio":0.585963,"impliedVol":0.893,"impliedVolPercentile":0.3625},"requestUrl":"/m/hq/s/GRAL","defaultTab":"news","newsList":[{"id":"1120392010","title":"异动解读｜GRAIL, Inc.盘中下跌5.35%，财报后营收逊预期叠加机构分歧压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1120392010","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120392010?lang=zh_cn&edition=full","pubTime":"2026-11-10 23:46","pubTimestamp":1794325619,"startTime":"0","endTime":"0","summary":"11月10日，GRAIL, Inc.盘中下跌5.35%，报121.23美元/股，成交额1882.87万美元。消息面上，公司此前披露第三季度每股亏损2.21美元，好于市场预期的亏损2.45美元，但季度营收为3754万美元，低于市场预期的4435万美元，业绩表现偏分化。同时，RBC虽将目标价由84美元上调至100美元，但仍维持行业表现评级；高盛亦维持持有评级并给出110美元目标价。市场交易主线仍围绕Galleri多癌早检后续审批、标签范围、报销覆盖及商业化兑现节奏展开。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"GRAIL盘中下挫，营收逊预期引发担忧","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100151345","title":"异动解读｜GRAIL, Inc.盘中上涨5.52%，财报优于预期叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1100151345","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100151345?lang=zh_cn&edition=full","pubTime":"2026-11-09 22:43","pubTimestamp":1794235383,"startTime":"0","endTime":"0","summary":"11月9日，GRAIL, Inc.盘中上涨5.52%，报125.44美元/股，成交额427.92万美元。消息面上，公司第三季度每股亏损2.21美元，好于市场预期的亏损2.45美元；同时，机构将目标价由84美元上调至100美元，但维持行业表现评级。当前交易主线仍围绕Galleri多癌早检产品后续商业化转化与监管落地节奏展开，市场继续关注审批后产品定位、标签范围及销售兑现速度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报超预期，GRAIL盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176155635","title":"异动解读｜GRAIL, Inc.盘中上涨5.06%，财报优于预期叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1176155635","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176155635?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:40","pubTimestamp":1793976017,"startTime":"0","endTime":"0","summary":"11月6日，GRAIL, Inc.盘中上涨5.06%，报125.69美元/股，成交额485.75万美元。消息面上，公司第三季度每股亏损2.21美元，好于市场预期的亏损2.45美元；同时，机构将目标价由84美元上调至100美元，但维持行业表现评级。从近期交易主线看，市场仍围绕Galleri多癌早检产品后续商业化转化与监管落地节奏展开博弈。此前Galleri已获得FDA顾问委员会推荐通过，资金继续关注审批后产品定位、标签范围及销售兑现速度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报优于预期，股价强势上攻","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129479552","title":"异动解读｜GRAIL, Inc.盘前上涨6.61%，财报后资金继续博弈Galleri商业化兑现节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1129479552","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129479552?lang=zh_cn&edition=full","pubTime":"2026-11-06 21:53","pubTimestamp":1793973182,"startTime":"0","endTime":"0","summary":"11月6日，GRAIL, Inc.盘前上涨6.61%，报125.1美元/股，成交额13.77万美元。消息面上，公司最新披露第三季度每股亏损2.21美元，好于市场预期的亏损2.45美元；同时，机构已将目标价由84美元上调至100美元，但仍维持行业表现评级。从交易主线看，市场关注点并未停留在单季亏损改善，而是继续聚焦Galleri多癌早检产品后续商业化转化与监管落地节奏，包括审批后产品定位、标签范围及销售兑现速度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"GRAIL财报亏损收窄，多癌早检商业化加速","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123205544","title":"异动解读｜GRAIL, Inc.盘中下跌13%，财报虽优于预期但市场继续博弈商业化兑现节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1123205544","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123205544?lang=zh_cn&edition=full","pubTime":"2026-11-05 22:45","pubTimestamp":1793889930,"startTime":"0","endTime":"0","summary":"11月5日，GRAIL, Inc.盘中下跌13%，报124.1美元/股，成交额2721.92万美元。消息面上，公司最新披露第三季度每股亏损2.21美元，好于市场预期的亏损2.45美元，但股价仍承压，显示资金关注点并未停留在单季亏损改善。结合此前市场交易线索，当前焦点仍集中在Galleri多癌早检产品后续商业化转化与监管落地节奏。尽管公司此前已迎来FDA顾问委员会推荐通过、机构上调目标价等催化，但市场更关注审批后产品定位、标签范围及销售兑现速度。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报虽优于预期，商业化兑现仍承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167036526","title":"异动解读｜GRAIL, Inc.盘前下跌8.81%，财报虽优于预期但市场继续博弈商业化兑现节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1167036526","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167036526?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:36","pubTimestamp":1793882209,"startTime":"0","endTime":"0","summary":"11月5日，GRAIL, Inc.盘前下跌8.81%，报130.33美元/股，成交额7.19万美元。消息面上，公司最新披露的第三季度每股亏损为2.21美元，好于市场预期的亏损2.45美元，但股价仍承压，显示资金关注点并未停留在单季亏损改善。Grail, Inc.于2015年9月11日在特拉华州注册成立。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报优于预期仍下跌，多癌早检商业化引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188729120","title":"异动解读｜GRAIL, Inc.夜盘下跌6.72%，财报虽优于预期但市场继续博弈商业化兑现节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1188729120","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188729120?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:05","pubTimestamp":1793840714,"startTime":"0","endTime":"0","summary":"11月5日，GRAIL, Inc.夜盘下跌6.72%，报134.0美元/股，成交额1888.0美元。消息面上，公司最新披露的第三季度每股亏损为2.21美元，好于市场预期的亏损2.45美元，但股价仍走弱，显示市场交易重心并未停留在单季亏损改善，而是继续聚焦Galleri多癌早检产品后续商业化转化与监管落地节奏。Grail, Inc.于2015年9月11日在特拉华州注册成立。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报超预期仍下跌，市场担忧商业化节奏","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175996544","title":"异动解读｜GRAIL, Inc.盘后下跌5.56%，财报后市场继续博弈商业化兑现与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1175996544","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175996544?lang=zh_cn&edition=full","pubTime":"2026-11-05 05:03","pubTimestamp":1793826190,"startTime":"0","endTime":"0","summary":"11月5日，GRAIL, Inc.盘后下跌5.56%，报143.62美元/股，成交额244.36万美元。消息面上，市场关注点仍围绕公司最新财报预期兑现情况，以及Galleri多癌早检产品在监管催化后能否进一步转化为商业化进展。此前市场已预期公司当季营收同比增长25.27%，EPS同比改善26.05%；Galleri此前获得FDA顾问委员会推荐通过，机构亦将目标价由105美元上调至175美元并维持买入评级，当前焦点已由审评结果转向产品定位、标签及后续落地节奏。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报后盘后下跌，商业化落地引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198731052","title":"异动解读｜GRAIL, Inc.盘中下跌5.08%，财报后市场继续博弈商业化兑现与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1198731052","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198731052?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:59","pubTimestamp":1793807953,"startTime":"0","endTime":"0","summary":"11月4日，GRAIL, Inc.盘中下跌5.08%，报132.36美元/股，成交额1854.66万美元。消息面上，市场关注点仍围绕公司最新财报预期兑现情况，以及Galleri多癌早检产品在监管催化后能否进一步转化为商业化进展。此前市场已预期公司当季营收同比增长25.27%，EPS同比改善26.05%；Galleri此前获得FDA顾问委员会推荐通过，机构亦将目标价由105美元上调至175美元并维持买入评级，当前焦点已由审评结果转向产品定位、标签及后续落地节奏。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL盘中下跌，财报后商业化落地引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108252022","title":"异动解读｜GRAIL, Inc.盘中上涨6.04%，财报前市场聚焦营收增长与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1108252022","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108252022?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:42","pubTimestamp":1793716929,"startTime":"0","endTime":"0","summary":"11月3日，GRAIL, Inc.盘中上涨6.04%，报142.0美元/股，成交额604.88万美元。消息面上，市场仍在关注公司即将披露的季度业绩，以及Galleri多癌早检产品在监管催化后能否进一步兑现商业化进展。已披露预期显示，公司本季度营收预计同比增长25.27%，EPS预计同比改善26.05%。此前Galleri已获FDA顾问委员会推荐通过，且有机构将目标价由105美元上调至175美元并维持买入评级，市场焦点正由审评结果转向产品定位、标签及后续落地节奏。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前夕，GRAIL盘中上涨引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128743459","title":"异动解读｜GRAIL盘中下跌5.87%，财报前市场聚焦营收增长与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1128743459","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128743459?lang=zh_cn&edition=full","pubTime":"2026-11-02 23:55","pubTimestamp":1793634912,"startTime":"0","endTime":"0","summary":"11月2日，GRAIL盘中下跌5.87%，报135.01美元/股，成交额3030.47万美元。消息面上，市场仍在关注公司即将披露的季度业绩，以及Galleri多癌早检产品在监管催化后能否进一步兑现商业化进展。已披露预期显示，公司本季度营收预计同比增长25.27%，EPS预计同比改善26.05%。此前Galleri已获FDA顾问委员会推荐通过，且有机构将目标价由105美元上调至175美元并维持买入评级，市场焦点正由审评结果转向产品定位、标签及后续落地节奏。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL盘中下挫，财报前聚焦营收增长与监管落地","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137185436","title":"异动解读｜GRAIL盘中下跌5.61%，财报前市场聚焦营收增长与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1137185436","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137185436?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:05","pubTimestamp":1793369150,"startTime":"0","endTime":"0","summary":"10月30日，GRAIL盘中下跌5.61%，报148.95美元/股，成交额2525.44万美元。消息面上，市场正关注公司即将披露的季度业绩，以及Galleri多癌早检产品在监管催化后能否进一步兑现商业化进展。已披露预期显示，公司本季度营收预计同比增长25.27%，EPS预计同比改善26.05%。此前Galleri已获FDA顾问委员会推荐通过，UBS随后将目标价由105美元上调至175美元并维持买入评级，市场焦点正由审评结果转向产品定位、标签及后续落地节奏。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL财报前承压下跌，营收与监管落地成焦点","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184812276","title":"异动解读｜GRAIL盘前下跌5.06%，财报前市场聚焦营收增长与监管落地节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=1184812276","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184812276?lang=zh_cn&edition=full","pubTime":"2026-10-30 21:29","pubTimestamp":1793366942,"startTime":"0","endTime":"0","summary":"10月30日，GRAIL盘前下跌5.06%，报150.25美元/股，成交额25.6万美元。消息面上，公司将于11月4日发布季度财报，市场目前关注监管催化后商业化兑现与经营质量变化。已披露预期显示，公司本季度营收预计同比增长25.27%，EPS预计同比改善26.05%。此前Galleri多癌早检产品已获FDA顾问委员会推荐通过，UBS随后将目标价由105美元上调至175美元并维持买入评级，市场焦点逐步由审评结果转向产品定位、标签及后续商业落地。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL财报在即盘前下跌，营收增长与商业化落地受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187285396","title":"财报前瞻 | GRAIL, Inc.本季度营收预计增25.27%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1187285396","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187285396?lang=zh_cn&edition=full","pubTime":"2026-10-29 00:00","pubTimestamp":1793203240,"startTime":"0","endTime":"0","summary":"GRAIL, Inc.将于2026年11月04日发布季度财报，市场关注监管催化与经营质量的同步变化。公司未披露本季度毛利率与净利率的量化预测。结合市场对本季度营收同比增长25.27%与EPS同比改善26.05%的预期，UBS认为公司正处于由监管预期转向商业兑现的关键过渡期，短期业绩弹性与中期成长确定性兼具，维持偏积极的前瞻判断。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | GRAIL, Inc.本季度营收预计增25.27%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159753014","title":"异动解读｜GRAIL盘中上涨5.43%，FDA审评利好后获投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1159753014","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159753014?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:54","pubTimestamp":1793195695,"startTime":"0","endTime":"0","summary":"10月28日，GRAIL盘中上涨5.43%，报158.455美元/股，成交额2122.74万美元。消息面上，公司Galleri多癌早检产品此前获FDA顾问委员会推荐通过，叠加UBS将目标价从105美元上调至175美元并维持买入评级，持续提振市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比，市场关注点已更多转向产品定位与标签，而非核心安全问题。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL获FDA利好推动，盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124942999","title":"异动解读｜GRAIL盘中上涨5.12%，FDA审评利好后获投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1124942999","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124942999?lang=zh_cn&edition=full","pubTime":"2026-10-27 22:38","pubTimestamp":1793111919,"startTime":"0","endTime":"0","summary":"10月27日，GRAIL盘中上涨5.12%，报146.72美元/股，成交额2295.38万美元。消息面上，Galleri多癌早检产品此前获FDA顾问委员会推荐通过，叠加UBS将目标价从105美元上调至175美元并维持买入评级，继续提振市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比。市场焦点已更多转向产品定位与标签，而非核心安全问题。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FDA审评利好，GRAIL盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115659631","title":"异动解读｜GRAIL盘中上涨5.61%，FDA审评利好后获投行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1115659631","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115659631?lang=zh_cn&edition=full","pubTime":"2026-10-26 23:01","pubTimestamp":1793026861,"startTime":"0","endTime":"0","summary":"10月26日，GRAIL盘中上涨5.61%，报139.99美元/股，成交额2181.49万美元。消息面上，公司Galleri多癌早检产品此前获得FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，继续提振市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比。市场焦点已更多转向产品定位与标签，而非核心安全问题。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL获FDA利好，投行上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109260230","title":"异动解读｜GRAIL盘中上涨5.05%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1109260230","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109260230?lang=zh_cn&edition=full","pubTime":"2026-10-23 23:59","pubTimestamp":1792771142,"startTime":"0","endTime":"0","summary":"10月23日，GRAIL盘中上涨5.05%，报133.48美元/股，成交额2194.93万美元。消息面上，公司Galleri多癌早检产品此前获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，持续强化市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比。市场关注点已更多转向产品定位与标签，而非核心安全问题。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FDA审评利好，GRAIL获投行大幅上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109483205","title":"异动解读｜GRAIL盘中下跌5.01%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1109483205","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109483205?lang=zh_cn&edition=full","pubTime":"2026-10-22 23:49","pubTimestamp":1792684151,"startTime":"0","endTime":"0","summary":"10月22日，GRAIL盘中下跌5.01%，报125.86美元／股，成交额2481.37万美元。消息面上，公司Galleri多癌早检产品此前获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比。市场关注点已更多转向产品定位与标签，而非核心安全问题，持续强化其监管落地与商业化前景预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL盘中下跌，FDA利好获投行大幅上调目标价","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112451021","title":"异动解读｜GRAIL盘中上涨5.35%，FDA审评利好后获投行大幅上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1112451021","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112451021?lang=zh_cn&edition=full","pubTime":"2026-10-21 22:30","pubTimestamp":1792593040,"startTime":"0","endTime":"0","summary":"10月21日，GRAIL盘中上涨5.35%，报131.34美元／股，成交额1421.59万美元。消息面上，公司Galleri多癌早检产品此前获美国FDA顾问委员会推荐通过，随后UBS将目标价从105美元上调至175美元，并维持买入评级，继续强化市场对其监管落地与商业化前景的预期。从审评结果看，顾问委员会以10比0支持安全性、6比4支持有效性、7比2且1票弃权支持获益风险比；市场关注点已更多转向产品定位与标签，而非核心安全问题，成为股价近期活跃的重要催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"GRAIL股价上涨，FDA利好催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://grail.com;investors.grail.com","stockEarnings":[{"period":"1week","weight":-0.0425},{"period":"1month","weight":-0.0889},{"period":"3month","weight":0.6969},{"period":"6month","weight":1.1181},{"period":"1year","weight":0.6131},{"period":"ytd","weight":0.4964}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Grail, Inc.于2015年9月11日在特拉华州注册成立。该公司是一家医疗保健公司，致力于通过开创癌症早期检测的新技术来拯救生命和改善健康。该公司建立了一个由科学家、工程师和医生组成的多学科组织，它正利用下一代测序（NGS）、人群规模临床研究以及最先进的计算机科学和数据科学的力量来克服医学的最大挑战之一。该公司利用该公司的平台技术，开发了一种多癌症早期检测血液检测方法，在临床研究中证明了从一次抽血中就可以检测出50多种癌症类型，并能高度准确地定位癌症信号。","exchange":"NASDAQ","name":"GRAIL, Inc.","nameEN":"GRAIL, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供GRAIL, Inc.(GRAL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"GRAIL, Inc.,GRAL,GRAIL, Inc.股票,GRAIL, Inc.股票老虎,GRAIL, Inc.股票老虎国际,GRAIL, Inc.行情,GRAIL, Inc.股票行情,GRAIL, Inc.股价,GRAIL, Inc.股市,GRAIL, Inc.股票价格,GRAIL, Inc.股票交易,GRAIL, Inc.股票购买,GRAIL, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRAIL, Inc.(GRAL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供GRAIL, Inc.(GRAL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}